Evidence map›Paper›PMID 35979528›Full record

ArticleJournal of health economics and outcomes research2022

Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States.

Ehab L Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin, Eric Q Wu, Pallavi Patwardhan

Open access · goldAbstract read
In one paragraph

Article in Journal of health economics and outcomes research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Real-world Management of CML: Outcomes and Treatment Patterns.Current hematologic malignancy reports · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Ehab L AtallahMedical College of Wisconsin, Milwaukee.
Rodrigo MaegawaNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Dominick Latremouille-ViauAnalysis Group, Inc, Montréal, Québec, Canada.
Carmine RossiAnalysis Group, Inc, Montréal, Québec, Canada.
Annie GuérinAnalysis Group, Inc, Montréal, Québec, Canada.
Eric Q WuAnalysis Group, Inc, Boston, Massachusetts.
Pallavi PatwardhanNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Group for Research in Decision Analysis · CANovartis (United States) · USAnalysis Group (United States) · USMedical College of Wisconsin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chronic myeloid leukemiacostseconomic burdenhealthcare resource utilizationMedicaretreatment patternstyrosine kinase inhibitors

Identifiers

PMID35979528
PMCPMC9352872
OpenAlexW4289856100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.